Transcriptional programming of translation by BCL6 controls skeletal muscle proteostasis.
Krithika RamachandranChristopher R FuttnerMeredith A SommarsMattia QuattrocelliYasuhiro OmuraEllen FruzynaJanice C WangNathan J WaldeckMadhavi D SenagolageCarmen G TellesAlexis R DemonbreunErin PrendergastNicola LaiDaniel ArangoIlya R BedermanElizabeth M McNallyGrant D BarishPublished in: Nature metabolism (2024)
Skeletal muscle is dynamically controlled by the balance of protein synthesis and degradation. Here we discover an unexpected function for the transcriptional repressor B cell lymphoma 6 (BCL6) in muscle proteostasis and strength in mice. Skeletal muscle-specific Bcl6 ablation in utero or in adult mice results in over 30% decreased muscle mass and force production due to reduced protein synthesis and increased autophagy, while it promotes a shift to a slower myosin heavy chain fibre profile. Ribosome profiling reveals reduced overall translation efficiency in Bcl6-ablated muscles. Mechanistically, tandem chromatin immunoprecipitation, transcriptomic and translational analyses identify direct BCL6 repression of eukaryotic translation initiation factor 4E-binding protein 1 (Eif4ebp1) and activation of insulin-like growth factor 1 (Igf1) and androgen receptor (Ar). Together, these results uncover a bifunctional role for BCL6 in the transcriptional and translational control of muscle proteostasis.